They'll still need to do a P3, from what I've read about accelerated approvals and still needing to go through the whole clinical trials pathway. For what it's worth, I believe a raise will/should happen irrespective of accelerated approval. I believe, as a company, you don't want to be looking down the barrel of a buyout with little funds., it doesn't allow you to negotiate from a position of strength.
whether for financial leverage or needing funds for a P3, I feel a raise will happen, but not for a long time and hopefully at a significantly higher SP.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.015(1.24%) |
Mkt cap ! $201.5M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.16 | $145.1K | 123.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2948 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 412 | 1 |
View Market Depth
| Last trade - 14.18pm 03/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |